Completed PHASE2 INTERVENTIONAL 1-arm NCT00807495

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Burkitt's Lymphoma Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

Interventions Alisertib

Updated 7 times since 2017 Last updated: Feb 27, 2018 Started: Feb 10, 2009 Primary completion: Jan 4, 2011 Completion: Feb 13, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Burkitt's Lymphoma and Diffuse Large B-cell Lymphoma and is currently completed. Millennium Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Apr 2018 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Millennium Pharmaceuticals, Inc.

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mount Holly, United States